Jacques Theurillat
InvestorPartner at Sofinnova Partners
Paris, France
Writes $100K – $5M checks · typically $1.5M
About
Jacques joined Sofinnova Partners in 2017 as a Partner in the Crossover Strategy, bringing extensive experience in biopharmaceutical operations and both private and public investing. He co-founded and managed Ares Life Sciences in 2008, deploying €1.25 billion across six life sciences companies, and previously spent nearly 20 years at the Serono pharmaceutical group in senior roles including deputy CEO, CFO, and head of strategic corporate development.
Contact· self-published, not guessed
Invests in
Biotech
Investments
Investor
Bronchus Technologies IncEsaote SpaEuromedic International BVGreer IncSanthera PharmaceuticalsStallergenes SA
Per the firm's website.
Colleagues at Sofinnova Partners
Network2
Investors connected to Jacques in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Jacques Theurillat?
- Jacques joined Sofinnova Partners in 2017 as a Partner in the Crossover Strategy, bringing extensive experience in biopharmaceutical operations and both private and public investing. He co-founded and managed Ares Life Sciences in 2008, deploying €1.25 billion across six life sciences companies, and previously spent nearly 20 years at the Serono pharmaceutical group in senior roles including deputy CEO, CFO, and head of strategic corporate development.
- Where does Jacques Theurillat work?
- Jacques Theurillat is Partner at Sofinnova Partners.
- What does Jacques Theurillat invest in?
- Jacques Theurillat invests in Biotech.
- What check size does Jacques Theurillat write?
- Jacques Theurillat typically writes checks of $100K – $5M.
- What companies has Jacques Theurillat invested in?
- Investments tracked here include Bronchus Technologies Inc, Esaote Spa, Euromedic International BV, Greer Inc, Santhera Pharmaceuticals, Stallergenes SA.